Serina Therapeutics, a clinical-stage biotechnology company, received a notice from the NYSE regarding its shareholders' equity.
The Company reported stockholders' equity of $1.6 million as of September 30, 2025, and had losses in three of its four most recent fiscal years.
NYSE notified Serina that it is below the continued listing criteria and must submit a plan by February 8, 2026.
The Company's listing is subject to periodic reviews until compliance is regained.
NYSE Deficiency Notification
Serina Therapeutics received a notice due to being below the listing criteria in terms of stockholders' equity and recent losses.
Plan Submission Deadline
Serina must submit a plan by February 8, 2026, outlining actions to regain compliance with NYSE listing standards.
Cure Period
The Company has until July 9, 2027, to comply with the continued listing standards after submitting an accepted plan.
- Serina's non-compliance with listing criteria could impact investor confidence and trading of its stock on NYSE.
- The Company's ability to regain compliance and maintain its listing status will be crucial for its future funding and growth prospects.
Serina Therapeutics faces challenges in maintaining its NYSE listing status but has a defined timeline to address the deficiencies and regain compliance.